HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Marinus Pharma (NASDAQ:MRNS) and maintained an $11 price target.

May 09, 2024 | 10:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Marinus Pharma with an $11 price target.
The reiteration of a Buy rating and maintenance of an $11 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in the stock's price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100